Protective effects of the dipeptidyl peptidase IV inhibitor sitagliptin in the blood-retinal barrier in a type 2 diabetes animal model

Diabetes, Obesity and Metabolism

Volumn 14, Issue 5, 2012, Pages 454-463

  Goncalves A ^a   Leal, E ^b   Paiva, A ^c   Teixeira Lemos, E ^a,d   Teixeira, F ^a   Ribeiro, C F ^a   Reis, F ^a   Ambrosio A F ^e,f   Fernandes, R ^a  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b UNIVERSITY OF COIMBRA   (Portugal)

^c CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

^d POLYTECHNIC INSTITUTE OF VISEU   (Portugal)

^e UNIVERSITY OF COIMBRA   (Portugal)

^f ASSOCIATION FOR INNOVATION AND BIOMEDICAL RESEARCH ON LIGHT AND IMAGE AIBILI   (Portugal)

Author keywords

Blood retinal barrier; Diabetic retinopathy; Dipeptidyl peptidase IV; Endothelial progenitor cells; Sitagliptin; Zucker Diabetic Fatty rat

Indexed keywords

3 NITROTYROSINE; CLAUDIN 5; DNA NUCLEOTIDYLEXOTRANSFERASE; HEMOGLOBIN A1C; INTERLEUKIN 1BETA; OCCLUDIN; PROTEIN BAX; PROTEIN BCL 2; SITAGLIPTIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BLOOD RETINA BARRIER; CD34 SELECTION; CELL ADHESION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DRUG EFFECT; ENDOTHELIAL PROGENITOR CELL; FLOW CYTOMETRY; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; IMMUNOHISTOCHEMISTRY; MALE; NICK END LABELING; NITROSATIVE STRESS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PERIPHERAL CIRCULATION; PROTEIN LOCALIZATION; RAT; RETINA BLOOD VESSEL; RETINA CELL; TIGHT JUNCTION; WESTERN BLOTTING; ZUCKER DIABETIC FATTY RAT;

EID: 84859444000     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2011.01548.x     Document Type: Article

References (40)

1. Fong DS, Aiello L, Gardner TW et al. Retinopathy in diabetes. Diabetes Care 2004; 27(Suppl. 1): S84-S87.
2. Sagaties MJ, Raviola G, Schaeffer S, Miller C. The structural basis of the inner blood-retina barrier in the eye of Macaca mulatta. Invest Ophthalmol Vis Sci 1987; 28: 2000-2014.
3. Cunha-Vaz J, Faria de Abreu JR, Campos AJ. Early breakdown of the blood-retinal barrier in diabetes. Br J Ophthalmol 1975; 59: 649-656.
4. Antonetti DA, Barber AJ, Hollinger LA, Wolpert EB, Gardner TW. Vascular endothelial growth factor induces rapid phosphorylation of tight junction proteins occludin and zonula occluden 1. A potential mechanism for vascular permeability in diabetic retinopathy and tumors. J Biol Chem 1999; 274: 23463-23467.
5. Barber AJ, Antonetti DA, Gardner TW. Altered expression of retinal occludin and glial fibrillary acidic protein in experimental diabetes. The Penn State Retina Research Group. Invest Ophthalmol Vis Sci 2000; 41: 3561-3568.
6. Leal EC, Manivannan A, Hosoya K et al. Inducible nitric oxide synthase isoform is a key mediator of leukostasis and blood-retinal barrier breakdown in diabetic retinopathy. Invest Ophthalmol Vis Sci 2007; 48: 5257-5265.
7. Leal EC, Martins J, Voabil P et al. Calcium dobesilate inhibits the alterations in tight junction proteins and leukocyte adhesion to retinal endothelial cells induced by diabetes. Diabetes 2010; 59: 2637-2645.
8. Antonetti DA, Barber AJ, Bronson SK et al. Diabetic retinopathy: seeing beyond glucose-induced microvascular disease. Diabetes 2006; 55: 2401-2411.
9. Kowluru RA, Odenbach S. Role of interleukin-1beta in the pathogenesis of diabetic retinopathy. Br J Ophthalmol 2004; 88: 1343-1347.
10. Lutty GA, Cao J, McLeod DS. Relationship of polymorphonuclear leukocytes to capillary dropout in the human diabetic choroid. Am J Pathol 1997; 151: 707-714.
11. Joussen AM, Murata T, Tsujikawa A, Kirchhof B, Bursell SE, Adamis AP. Leukocyte-mediated endothelial cell injury and death in the diabetic retina. Am J Pathol 2001; 158: 147-152.
12. Joussen AM, Poulaki V, Mitsiades N et al. Nonsteroidal anti-inflammatory drugs prevent early diabetic retinopathy via TNF-alpha suppression. FASEB J 2002; 16: 438-440.
13. Asahara T, Murohara T, Sullivan A et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997; 275: 964-967.
14. Tepper OM, Galiano RD, Capla JM et al. Human endothelial progenitor cells from type II diabetics exhibit impaired proliferation, adhesion, and incorporation into vascular structures. Circulation 2002; 106: 2781-2786.
15. Fadini GP, Miorin M, Facco M et al. Circulating endothelial progenitor cells are reduced in peripheral vascular complications of type 2 diabetes mellitus. J Am Coll Cardiol 2005; 45: 1449-1457.
16. Bento CF, Fernandes R, Matafome P, Sena C, Seica R, Pereira P. Methylglyoxal-induced imbalance in the ratio of vascular endothelial growth factor to angiopoietin 2 secreted by retinal pigment epithelial cells leads to endothelial dysfunction. Exp Physiol 2010; 95: 955-970.
17. Fadini GP, Boscaro E, Albiero M et al. The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes: possible role of stromal-derived factor-1alpha. Diabetes Care 2010; 33: 1607-1609.
18. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006; 368: 1696-1705.
19. Clark JB, Palmer CJ, Shaw WN. The diabetic Zucker fatty rat. Proc Soc Exp Biol Med 1983; 173: 68-75.
20. Ferreira L, Teixeira-de-Lemos E, Pinto F et al. Effects of sitagliptin treatment on dysmetabolism, inflammation, and oxidative stress in an animal model of type 2 diabetes (ZDF rat). Mediators Inflamm 2010; 2010: 592760.
21. Danis RP, Yang Y. Microvascular retinopathy in the Zucker diabetic fatty rat. Invest Ophthalmol Vis Sci 1993; 34: 2367-2371.
22. Behl Y, Krothapalli P, Desta T, Roy S, Graves DT. FOXO1 plays an important role in enhanced microvascular cell apoptosis and microvascular cell loss in type 1 and type 2 diabetic rats. Diabetes 2009; 58: 917-925.
23. Sutherland DR, Anderson L, Keeney M, Nayar R, Chin-Yee I. The ISHAGE guidelines for CD34+ cell determination by flow cytometry. International Society of Hematotherapy and Graft Engineering. J Hematother 1996; 5: 213-226.
24. Kikuchi-Taura A, Soma T, Matsuyama T, Stern DM, Taguchi A. A new protocol for quantifying CD34(+) cells in peripheral blood of patients with cardiovascular disease. Tex Heart Inst J 2006; 33: 427-429.
25. Oltman CL, Davidson EP, Coppey LJ et al. Vascular and neural dysfunction in Zucker diabetic fatty rats: a difficult condition to reverse. Diabetes Obes Metab 2008; 10: 64-74.
26. Xiang J, Chao DT, Korsmeyer SJ. BAX-induced cell death may not require interleukin 1 beta-converting enzyme-like proteases. Proc Natl Acad Sci U S A 1996; 93: 14559-14563.
27. Kale G, Naren AP, Sheth P, Rao RK. Tyrosine phosphorylation of occludin attenuates its interactions with ZO-1, ZO-2, and ZO-3. Biochem Biophys Res Commun 2003; 302: 324-329.
28. Du Y, Smith MA, Miller CM, Kern TS. Diabetes-induced nitrative stress in the retina, and correction by aminoguanidine. J Neurochem 2002; 80: 771-779.
29. Oeseburg H, de Boer RA, Buikema H, van der Harst P, van Gilst WH, Sillje HH. Glucagon-like peptide 1 prevents reactive oxygen species-induced endothelial cell senescence through the activation of protein kinase A. Arterioscler Thromb Vasc Biol 2010; 30: 1407-1414.
30. Carmo A, Cunha-Vaz JG, Carvalho AP, Lopes MC. Effect of cyclosporin-A on the blood-retinal barrier permeability in streptozotocin-induced diabetes. Mediators Inflamm 2000; 9: 243-248.
31. Dobrian AD, Ma Q, Lindsay JW et al. Dipeptidyl peptidase IV inhibitor sitagliptin reduces local inflammation in adipose tissue and in pancreatic islets of obese mice. Am J Physiol Endocrinol Metab 2011; 300: E410-421.
32. Kowluru RA, Chan PS. Oxidative stress and diabetic retinopathy. Exp Diabetes Res 2007; 2007: 43603.
33. Kim SJ, Winter K, Nian C, Tsuneoka M, Koda Y, McIntosh CH. Glucose-dependent insulinotropic polypeptide (GIP) stimulation of pancreatic beta-cell survival is dependent upon phosphatidylinositol 3-kinase (PI3K)/protein kinase B (PKB) signaling, inactivation of the forkhead transcription factor Foxo1, and down-regulation of bax expression. J Biol Chem 2005; 280: 22297-22307.
34. Wang Q, Brubaker PL. Glucagon-like peptide-1 treatment delays the onset of diabetes in 8 week-old db/db mice. Diabetologia 2002; 45: 1263-1273.
35. Zhang Y, Wang Q, Zhang J, Lei X, Xu GT, Ye W. Protection of exendin-4 analogue in early experimental diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol 2009; 247: 699-706.
36. Brunner S, Schernthaner GH, Satler M et al. Correlation of different circulating endothelial progenitor cells to stages of diabetic retinopathy: first in vivo data. Invest Ophthalmol Vis Sci 2009; 50: 392-398.
37. Fadini GP, Coracina A, Baesso I et al. Peripheral blood CD34+KDR+ endothelial progenitor cells are determinants of subclinical atherosclerosis in a middle-aged general population. Stroke 2006; 37: 2277-2282.
38. Werner N, Kosiol S, Schiegl T et al. Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med 2005; 353: 999-1007.
39. Majka M, Janowska-Wieczorek A, Ratajczak J et al. Numerous growth factors, cytokines, and chemokines are secreted by human CD34(+) cells, myeloblasts, erythroblasts, and megakaryoblasts and regulate normal hematopoiesis in an autocrine/paracrine manner. Blood 2001; 97: 3075-3085.
40. Albiero M, Menegazzo L, Boscaro E, Agostini C, Avogaro A, Fadini GP. Defective recruitment, survival and proliferation of bone marrow-derived progenitor cells at sites of delayed diabetic wound healing in mice. Diabetologia 2011; 54: 945-953.